# 2025-18001: FDA Targets Scorched Esophagus with Drug Guidelines

2025-18001, Erosive Esophagitis: Developing Drugs for Treatment; Draft Guidance for Industry; Availability, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2025-09-17, effective Not specified in the document text (as of 2026-06-08).

- Canonical: https://policyrisk.com/federal-register/2025-18001
- As of: 2026-06-08
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2025-18001
- Title: Erosive Esophagitis: Developing Drugs for Treatment; Draft Guidance for Industry; Availability
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 90 FR 44825
- Published: 2025-09-17
- Effective: Not specified in the document text
- Comments close: 2025-11-17
- Significant: no
- Touches household money: no
- Regulation identifier numbers: none
- Last updated: 2026-06-08

## In one line

FDA Targets Scorched Esophagus with Drug Guidelines

## Summary

The FDA just dropped a draft guide to help drug makers create better treatments for erosive esophagitis, a painful throat condition. This guide explains how to run smart clinical trials to prove new drugs work and stay safe. Drug developers should check it out soon to speed up making effective medicines and bring relief to adults faster.

## Abstract

The Food and Drug Administration (FDA, Agency, or we) is announcing the availability of a draft guidance for industry entitled "Erosive Esophagitis: Developing Drugs for Treatment." The draft guidance details recommendations on clinical trials for drugs being developed for the healing of erosive esophagitis (EE) and maintenance of healed EE in adults, including considerations for eligibility criteria, trial design features, efficacy evaluations, and safety assessments.

## Effects PRIA read

No economic effects identified for this document.

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2025-18001 on federalregister.gov](https://www.federalregister.gov/documents/2025/09/17/2025-18001/erosive-esophagitis-developing-drugs-for-treatment-draft-guidance-for-industry-availability)
- [2025-18001 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2025-09-17/pdf/2025-18001.pdf)

## Related
- [Previous: 2025-18000, Symptomatic Nonerosive Gastroesophageal Reflux Disease: Developing Drugs for Tr…](https://policyrisk.com/federal-register/2025-18000)
- [Next: 2025-18002, Disseminated Coccidioidomycosis: Developing Drugs for Treatment; Draft Guidance…](https://policyrisk.com/federal-register/2025-18002)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2025-18001 (as of 2026-06-08).
